Chronic Kidney Disease
An estimated 3 million people in the UK live with chronic kidney disease, most of whom are undiagnosed. SGLT2 inhibitors have transformed treatment.
- ≈ 3.25m
people in the UK are living with chronic kidney disease at stages 3–5.
Source: Kidney Research UK, 2023
- eGFR + ACR
two-test staging recommended by NICE NG203.
Source: NICE, 2023
- DAPA-CKD
dapagliflozin reduced kidney failure and CV death by 39%.
Source: NEJM, 2020
eGFR and ACR together
NICE NG203 stages CKD using both estimated glomerular filtration rate (eGFR) and urinary albumin–creatinine ratio (ACR). Albuminuria is now recognised as an independent driver of cardiovascular and renal risk.[2]NICE NG203
ACEi/ARB plus SGLT2 inhibitor
NICE recommends ACE inhibitors or ARBs as first-line for CKD with hypertension or albuminuria, with dapagliflozin offered to many adults with CKD irrespective of diabetes status — based on the DAPA-CKD trial showing a 39% reduction in the composite of kidney failure, ≥ 50% eGFR decline, and renal or CV death.[5]DAPA-CKD
- [1] NHS. Chronic kidney disease (CKD) · 2024
- [2] NICE. Chronic kidney disease: assessment and management — NG203 · 2021 (updated 2023)
- [3] Kidney Research UK. Kidney disease: a UK public health emergency · 2023
- [4] UK Kidney Association. UK Renal Registry annual report · 2024
- [5] Heerspink et al., NEJM (DAPA-CKD). Dapagliflozin in patients with chronic kidney disease · 2020